Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer

C. D. Blanke, H. Choy, M. Teng, R. D. Beauchamp, S. Leach, J. Roberts, K. Washington, D. H. Johnson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Esophageal cancer is a major cause of morbidity and mortality worldwide. Although patients often present with apparently resectable disease, systemic spread frequently occurs before the development of symptoms and detection of tumor. The use of combined chemoradiation therapy, particularly before resection, appears to prolong survival and increase cure rates in certain histologic subtypes. Four randomized phase III trials compared preoperative chemoradiotherapy plus surgery with surgery alone. In trials including only patients with squamous histology, no improvement in survival was observed with preoperative chemoradiation therapy; however, in a trial including only patients with adenocarcinoma histology, improved median and overall survival were observed. Paclitaxel has been evaluated as a single agent in a phase U trial in previously untreated patients with locally advanced unresectable or metastatic esophageal cancer; the overall response rate was 32% and median survival was 13.2 months. Paclitaxel-based combinations also have been evaluated in esophageal cancer; particularly encouraging preliminary results have been achieved with paclitaxel/cisplatin/5-fluorouracil. Because paclitaxel is a potent radiosensitizer, it also has been evaluated in combination with radiation therapy for esophageal and other thoracic cancers, alone and in combination with other chemotherapeutic agents. Preliminary results suggest that neoadjuvant therapy with paclitaxel-based combinations (including 5-fluorouracil and cisplatin) and radiation is highly active, with variable toxicity. A goal of future trials is to assess paclitaxel-based combined modality therapy in combination with other new chemotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalSeminars in Radiation Oncology
Volume9
Issue number2 SUPPL. 1
StatePublished - 1999

Fingerprint

Esophageal Neoplasms
Paclitaxel
Thorax
cancer
therapy
irradiation
Survival
histology
surgery
Fluorouracil
Histology
drugs
Combined Modality Therapy
Neoadjuvant Therapy
mortality
Chemoradiotherapy
toxicity
Cisplatin
radiation therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Blanke, C. D., Choy, H., Teng, M., Beauchamp, R. D., Leach, S., Roberts, J., ... Johnson, D. H. (1999). Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Seminars in Radiation Oncology, 9(2 SUPPL. 1), 43-52.

Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. / Blanke, C. D.; Choy, H.; Teng, M.; Beauchamp, R. D.; Leach, S.; Roberts, J.; Washington, K.; Johnson, D. H.

In: Seminars in Radiation Oncology, Vol. 9, No. 2 SUPPL. 1, 1999, p. 43-52.

Research output: Contribution to journalArticle

Blanke, CD, Choy, H, Teng, M, Beauchamp, RD, Leach, S, Roberts, J, Washington, K & Johnson, DH 1999, 'Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer', Seminars in Radiation Oncology, vol. 9, no. 2 SUPPL. 1, pp. 43-52.
Blanke CD, Choy H, Teng M, Beauchamp RD, Leach S, Roberts J et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Seminars in Radiation Oncology. 1999;9(2 SUPPL. 1):43-52.
Blanke, C. D. ; Choy, H. ; Teng, M. ; Beauchamp, R. D. ; Leach, S. ; Roberts, J. ; Washington, K. ; Johnson, D. H. / Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. In: Seminars in Radiation Oncology. 1999 ; Vol. 9, No. 2 SUPPL. 1. pp. 43-52.
@article{d7735fa2c91f4d9897176dc14396ab87,
title = "Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer",
abstract = "Esophageal cancer is a major cause of morbidity and mortality worldwide. Although patients often present with apparently resectable disease, systemic spread frequently occurs before the development of symptoms and detection of tumor. The use of combined chemoradiation therapy, particularly before resection, appears to prolong survival and increase cure rates in certain histologic subtypes. Four randomized phase III trials compared preoperative chemoradiotherapy plus surgery with surgery alone. In trials including only patients with squamous histology, no improvement in survival was observed with preoperative chemoradiation therapy; however, in a trial including only patients with adenocarcinoma histology, improved median and overall survival were observed. Paclitaxel has been evaluated as a single agent in a phase U trial in previously untreated patients with locally advanced unresectable or metastatic esophageal cancer; the overall response rate was 32{\%} and median survival was 13.2 months. Paclitaxel-based combinations also have been evaluated in esophageal cancer; particularly encouraging preliminary results have been achieved with paclitaxel/cisplatin/5-fluorouracil. Because paclitaxel is a potent radiosensitizer, it also has been evaluated in combination with radiation therapy for esophageal and other thoracic cancers, alone and in combination with other chemotherapeutic agents. Preliminary results suggest that neoadjuvant therapy with paclitaxel-based combinations (including 5-fluorouracil and cisplatin) and radiation is highly active, with variable toxicity. A goal of future trials is to assess paclitaxel-based combined modality therapy in combination with other new chemotherapeutic agents.",
author = "Blanke, {C. D.} and H. Choy and M. Teng and Beauchamp, {R. D.} and S. Leach and J. Roberts and K. Washington and Johnson, {D. H.}",
year = "1999",
language = "English (US)",
volume = "9",
pages = "43--52",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer

AU - Blanke, C. D.

AU - Choy, H.

AU - Teng, M.

AU - Beauchamp, R. D.

AU - Leach, S.

AU - Roberts, J.

AU - Washington, K.

AU - Johnson, D. H.

PY - 1999

Y1 - 1999

N2 - Esophageal cancer is a major cause of morbidity and mortality worldwide. Although patients often present with apparently resectable disease, systemic spread frequently occurs before the development of symptoms and detection of tumor. The use of combined chemoradiation therapy, particularly before resection, appears to prolong survival and increase cure rates in certain histologic subtypes. Four randomized phase III trials compared preoperative chemoradiotherapy plus surgery with surgery alone. In trials including only patients with squamous histology, no improvement in survival was observed with preoperative chemoradiation therapy; however, in a trial including only patients with adenocarcinoma histology, improved median and overall survival were observed. Paclitaxel has been evaluated as a single agent in a phase U trial in previously untreated patients with locally advanced unresectable or metastatic esophageal cancer; the overall response rate was 32% and median survival was 13.2 months. Paclitaxel-based combinations also have been evaluated in esophageal cancer; particularly encouraging preliminary results have been achieved with paclitaxel/cisplatin/5-fluorouracil. Because paclitaxel is a potent radiosensitizer, it also has been evaluated in combination with radiation therapy for esophageal and other thoracic cancers, alone and in combination with other chemotherapeutic agents. Preliminary results suggest that neoadjuvant therapy with paclitaxel-based combinations (including 5-fluorouracil and cisplatin) and radiation is highly active, with variable toxicity. A goal of future trials is to assess paclitaxel-based combined modality therapy in combination with other new chemotherapeutic agents.

AB - Esophageal cancer is a major cause of morbidity and mortality worldwide. Although patients often present with apparently resectable disease, systemic spread frequently occurs before the development of symptoms and detection of tumor. The use of combined chemoradiation therapy, particularly before resection, appears to prolong survival and increase cure rates in certain histologic subtypes. Four randomized phase III trials compared preoperative chemoradiotherapy plus surgery with surgery alone. In trials including only patients with squamous histology, no improvement in survival was observed with preoperative chemoradiation therapy; however, in a trial including only patients with adenocarcinoma histology, improved median and overall survival were observed. Paclitaxel has been evaluated as a single agent in a phase U trial in previously untreated patients with locally advanced unresectable or metastatic esophageal cancer; the overall response rate was 32% and median survival was 13.2 months. Paclitaxel-based combinations also have been evaluated in esophageal cancer; particularly encouraging preliminary results have been achieved with paclitaxel/cisplatin/5-fluorouracil. Because paclitaxel is a potent radiosensitizer, it also has been evaluated in combination with radiation therapy for esophageal and other thoracic cancers, alone and in combination with other chemotherapeutic agents. Preliminary results suggest that neoadjuvant therapy with paclitaxel-based combinations (including 5-fluorouracil and cisplatin) and radiation is highly active, with variable toxicity. A goal of future trials is to assess paclitaxel-based combined modality therapy in combination with other new chemotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0032901564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032901564&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 43

EP - 52

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2 SUPPL. 1

ER -